Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Andrea G S BugginsAntonella ZucchettoKevin NorrisErika TissinoJerry PoleselZarni SoeDavid John AllsupAnna HockadayPei Loo OwPeter HillmenAndrew RawstronDaniel CatovskyPietro BulianRiccardo BombenDuncan M BairdChristopher D FeganValter GatteiChristopher J PepperPublished in: Leukemia (2021)